Kehoe Law Firm, P.C. informs investors that on February 7, 2025, a federal securities class action complaint was filed against Transocean Ltd. (“Transocean” or the “Company”) (NYSE:RIG) in United States District Court, Southern District of New York, on behalf of investors who purchased or otherwise acquired Transocean securities between May 1, 2023 and September 2, 2024, inclusive (the “Class Period”). 

Class Action Complaint Allegations 

Throughout the Class Period, the defendants allegedly failed to disclose that the Discoverer Inspiration and the Development Driller III were considered non-strategic assets; Transocean’s recorded asset valuations were overstated; and the sale of these rigs would result in a significant impairment charge of nearly twice the sale price of the vessels.

According to the complaint, “[i]nvestors began to question the veracity of [d]efendants’ public statements on September 3, 2024 when Transocean announced, while the market was closed, ‘as part of the Company’s effort to dispose of non-strategic assets[,]’ the Company had agreed to sell the Development Driller III and the Discoverer Inspiration and associated other assets for an aggregate $342 million.”

Transocean, according to the complaint, “. . . further announced that the sales would result in an estimated third-quarter non-cash charge of up to $645 million associated with the impairment of said assets. Therefore, the Company’s expected proceeds from the sale of the two aforementioned rigs was only approximately half the impairment the Company was required to take for the sale.”

When this news entered the market, Transocean’s stock price declined, closing at $4.32 per share on September 3, 2024.

Transocean Investors May Have Legal Claims

Investors who acquired Transocean stock during the Class Period may have legal claims. To learn more about the class action lawsuit or explore your legal options, please send us a message or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, no-obligation legal evaluation.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating whether certain executive officers and directors of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) breached their fiduciary duties by failing to manage Revance in an acceptable manner and whether Revance and its shareholders were harmed as a result.

Key Issues Under Investigation

The investigation concerns whether Revance’s officers and directors made materially false and misleading statements or failed to disclose critical information regarding:

1. Breach of the Distribution Agreement – Whether Revance materially breached its distribution agreement with Teoxane SA, thereby increasing the company’s risk of litigation; and
2. Potential Delay or Amendment of the Tender Offer – Whether the Tender Offer, pursuant to a merger agreement with Crown Laboratories, Inc., was likely to be delayed or amended due to a breach of the distribution agreement.

Revance Stock Investors: Learn More About the Investigation and Your Legal Options 

To learn more about the investigation or discuss potential legal claims, please send us a message or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, no-obligation legal evaluation.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff-side class action law firm specializing in securities fraud, breaches of fiduciary duties, and corporate misconduct. Collectively, the firm’s partners have served as Lead Counsel or Co-Lead Counsel in high-profile cases that have recovered more than $10 billion for both institutional and individual investors.

Our class action legal services are on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

A federal securities class action has been filed against Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) on behalf of investors who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents issued in connection with the company’s initial public offering (“IPO”) and suffered damages as a result.

The lawsuit asserts strict liability claims under the Securities Act of 1933 related to Neumora’s IPO, which commenced on or about September 15, 2023, offering 14,710,000 shares of common stock at a price of $17.00 per share.

Allegations Against Neumora 

Acccording to the complaint, the Offering Documents failed to disclose and/or misrepresented the following significant, then-existing material events, trends, and uncertainties regarding the prospects of Navacaprant as a monotherapy, including:

1. Changes to Trial Inclusion Criteria – To justify conducting its Phase Three Program, Neumora had to amend BlackThorn’s original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder (“MDD”) to show that Navacaprant offered a statistically significant improvement in treating MDD.

2. Modification to Statistical Analysis – Neumora also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD.

3. Insufficient Phase Two Trial Data – The Phase Two Trials lacked adequate data, particularly regarding patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.

Investors Who Acquired NMRA Stock May Have Legal Claims

Investors who acquired Neumora common stock pursuant or traceable to the company’s IPO may have legal claims. To learn more about the Neumora class action or explore your legal options, please send us a message or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, no-obligation legal evaluation.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff-side class action law firm specializing in securities fraud, breaches of fiduciary duties, and corporate misconduct. Collectively, the firm’s partners have served as Lead Counsel or Co-Lead Counsel in high-profile cases that have recovered more than $10 billion for both institutional and individual investors.

Kehoe Law Firm’s legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating whether certain executive officers and directors of Warner Bros. Discovery, Inc. (“Warner Bros.” or “WBD”) (NASDAQ: WBD) failed to manage Warner Bros. in an acceptable manner, in breach of their fiduciary duties to Warner Bros. and whether WBD and its shareholders were harmed as a result.

Warner Bros., Media Rights, and the NBA 

The breach of fiduciary duties investigation concerns whether WBD made materially false and misleading statements regarding its business prospects, particularly its media rights negotiations with the National Basketball Association (“NBA”) and the financial health of its Networks Segment.

More specifically, the investigation concerns whether WBD and its executives misled investors by failing to disclose key risks, including:

1. The likelihood that the NBA negotiations would require a major reassessment of WBD’s business operations and goodwill valuations;
2. The deterioration of the Networks Segment’s goodwill due to the gap between WBD’s market capitalization and book value; weakness across U.S. advertising markets; and uncertainty surrounding affiliate relationships and sports rights renewals, especially regarding the NBA contract;
3. The increased probability of goodwill impairment charges amounting to billions of dollars;
4. Whether these factors, if not disclosed, resulted in an artificially inflated and misleading portrayal of WBD’s financial position.

Current Warner Bros. Stock Investors: Learn More About the Investigation and Your Legal Options 

To learn more about the investigation or discuss potential legal claims, please send us a message or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], for a free, no-obligation legal evaluation.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff-side class action law firm specializing in securities fraud, breaches of fiduciary duties, and corporate misconduct. Collectively, the firm’s partners have served as Lead Counsel or Co-Lead Counsel in high-profile cases that have recovered more than $10 billion for both institutional and individual investors.

Our class action legal services are on a contingency-fee basis, meaning you are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]